Turkey-based science-focused company expands U.S. availability with research-driven botanical formulations coming soon to Amazon. The post Carmed PharmaceuticalsTurkey-based science-focused company expands U.S. availability with research-driven botanical formulations coming soon to Amazon. The post Carmed Pharmaceuticals

Carmed Pharmaceuticals to Launch Standardized Carvacrol Formulations on Amazon

2026/03/24 18:00
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Boca Raton, Florida (Newsworthy.ai) Tuesday Mar 24, 2026 @ 4:00 AM Mountain —

Carmed Pharmaceuticals, a science-driven company specializing in standardized carvacrol-based formulations, announced plans to expand its U.S. presence with an upcoming launch on Amazon.

The expansion builds on Carmed’s entry into the United States market and represents the next step in making its research-driven botanical formulations more accessible to U.S. consumers through one of the world’s largest online retail platforms.

Carmed’s approach integrates traditional botanical knowledge with modern pharmaceutical methodology to develop standardized formulations designed to support immune resilience, cellular health, and overall physiological balance.

Expanding Access Through Amazon

The planned Amazon launch is designed to provide broader access to Carmed’s formulations while supporting the company’s long-term strategy of combining scientific development with scalable distribution.

By leveraging Amazon’s platform, Carmed aims to reach a wider audience seeking standardized, quality-controlled botanical formulations grounded in research and formulation science.

“Amazon allows us to make our formulations more accessible while maintaining our focus on scientific integrity and standardization,” said Mustafa Can, Founder of Carmed Pharmaceuticals. “Our goal is to ensure that every product reflects the same level of research, consistency, and quality that defines our development process.”

The company’s U.S. rollout is focused on accessibility, consistency, and maintaining alignment with regulatory standards as it expands into new distribution channels.

Product Portfolio Coming to Amazon

As part of its Amazon launch, Carmed Pharmaceuticals plans to introduce several of its flagship formulations:

  • Vacrol® Kids Spray – A carvacrol-based spray formulated to support upper respiratory wellness and microbial balance for children ages 4-11.

  • S-Mix® – A synergy-driven formulation designed to support immune function and healthy cellular activity.

  • Vacrol® Capsule – A standardized carvacrol formulation developed to support microbial balance and immune resilience.

  • Vacrol-M® Capsule – A multi-component botanical formulation designed to support immune function and respiratory wellness.

  • Omevaq-3® – A targeted formulation developed to support cellular energy metabolism and cognitive wellness.

Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified.

According to the company, Carmed’s formulations are developed using standardized processes designed to ensure consistency, reproducibility, and quality control across product batches.

Scientific Foundation and Ongoing Research

Carmed’s development model is supported by ongoing research and collaboration with academic institutions, laboratories, and medical researchers focused on formulation science and bioactive compound evaluation.

In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based formulations and multicomponent botanical interactions.

The company emphasizes that such research reflects scientific investigation into botanical bioactivity and formulation design and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

U.S. Market Expansion

Carmed states that its U.S. strategy is centered on building long-term credibility through scientific rigor, regulatory alignment, and consistent product quality as it expands distribution.

“The Amazon launch is an important step in making Carmed’s formulations available to a broader audience in the United States,” said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. “We are focused on delivering consistent, high-quality products while continuing to build awareness around our research-driven approach to formulation development.”

The Amazon launch represents a key milestone in that strategy, enabling broader consumer access while supporting continued investment in research and formulation development.

Availability timelines and product listings on Amazon will be announced in the coming weeks.

About Carmed Pharmaceuticals

Carmed Pharmaceuticals is a research-driven company specializing in standardized, mechanism-based botanical formulations rooted in Anatolia’s rich botanical heritage. Integrating traditional plant knowledge with modern pharmaceutical technology, Carmed focuses on analytical validation, quality control, and reproducible formulation design.

Officially established in 2019 following years of focused research and development, the company operates with nearly 15 years of industry experience. All products are manufactured in accordance with Good Manufacturing Practice (GMP) principles and relevant regulatory standards, emphasizing safe production, environmental awareness, and continuous quality improvement.

Carmed develops standardized formulations designed to support preventive wellness, immune resilience, and cellular health through science-informed, quality-controlled processes.

Visit Carmed Pharmaceuticals website and visit them on Instagram.


This press release is distributed by the Newsworthy.ai™ Press Release Newswire – News Marketing Platform™. The reference URL for this press release is located here Carmed Pharmaceuticals to Launch Standardized Carvacrol Formulations on Amazon.

The post Carmed Pharmaceuticals to Launch Standardized Carvacrol Formulations on Amazon appeared first on citybuzz.

Market Opportunity
Union Logo
Union Price(U)
$0.0009392
$0.0009392$0.0009392
-5.14%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Siren Token Sheds 70% as Analysts Question Supply Structure

Siren Token Sheds 70% as Analysts Question Supply Structure

The post Siren Token Sheds 70% as Analysts Question Supply Structure appeared on BitcoinEthereumNews.com. The Siren (SIREN) token plunged nearly 70% on Tuesday,
Share
BitcoinEthereumNews2026/03/25 01:00
ArtGis Finance Partners with MetaXR to Expand its DeFi Offerings in the Metaverse

ArtGis Finance Partners with MetaXR to Expand its DeFi Offerings in the Metaverse

By using this collaboration, ArtGis utilizes MetaXR’s infrastructure to widen access to its assets and enable its customers to interact with the metaverse.
Share
Blockchainreporter2025/09/18 00:07
Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be

The post Why The Green Bay Packers Must Take The Cleveland Browns Seriously — As Hard As That Might Be appeared on BitcoinEthereumNews.com. Jordan Love and the Green Bay Packers are off to a 2-0 start. Getty Images The Green Bay Packers are, once again, one of the NFL’s better teams. The Cleveland Browns are, once again, one of the league’s doormats. It’s why unbeaten Green Bay (2-0) is a 8-point favorite at winless Cleveland (0-2) Sunday according to betmgm.com. The money line is also Green Bay -500. Most expect this to be a Packers’ rout, and it very well could be. But Green Bay knows taking anyone in this league for granted can prove costly. “I think if you look at their roster, the paper, who they have on that team, what they can do, they got a lot of talent and things can turn around quickly for them,” Packers safety Xavier McKinney said. “We just got to kind of keep that in mind and know we not just walking into something and they just going to lay down. That’s not what they going to do.” The Browns certainly haven’t laid down on defense. Far from. Cleveland is allowing an NFL-best 191.5 yards per game. The Browns gave up 141 yards to Cincinnati in Week 1, including just seven in the second half, but still lost, 17-16. Cleveland has given up an NFL-best 45.5 rushing yards per game and just 2.1 rushing yards per attempt. “The biggest thing is our defensive line is much, much improved over last year and I think we’ve got back to our personality,” defensive coordinator Jim Schwartz said recently. “When we play our best, our D-line leads us there as our engine.” The Browns rank third in the league in passing defense, allowing just 146.0 yards per game. Cleveland has also gone 30 straight games without allowing a 300-yard passer, the longest active streak in the NFL.…
Share
BitcoinEthereumNews2025/09/18 00:41